Cancer vaccine

Targovax Hosts Conference Call 12 June 2018

Retrieved on: 
Tuesday, June 12, 2018
Vaccination, Experimental cancer treatments, Medicine, Adenoviridae, Virotherapy, Biotechnology, Biology, Oncolytic virus, Oncolytic adenovirus, Clinical medicine, Cancer vaccine, Vaccine

Targovax (OSE:TRVX) is a clinical stage company focused on developing and commercializing immune activators to target hard to treat solid tumors.

Key Points: 
  • Targovax (OSE:TRVX) is a clinical stage company focused on developing and commercializing immune activators to target hard to treat solid tumors.
  • Targovax's primary product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, used as potential multi-target, neo-antigen therapeutic cancer vaccines.
  • In addition, Targovax has a neo-antigen cancer vaccine under development targeting tumors that express mutated forms of RAS.
  • Both platforms are protected by an extensive portfolio of IP, know-how, and have the potential to yield multiple product candidates.

Targovax to Present at Jefferies 2018 Global Healthcare Conference

Retrieved on: 
Monday, June 4, 2018
Vaccination, Medicine, Experimental cancer treatments, Clinical medicine, Oncolytic virus, Cancer vaccine, Health, Cancer immunotherapy, Vaccine, Adenoviridae, Virotherapy, Virus

Targovax (OSE:TRVX) is a clinical stage company focused on developing and commercializing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors.

Key Points: 
  • Targovax (OSE:TRVX) is a clinical stage company focused on developing and commercializing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors.
  • The Company's development pipeline is based on two novel proprietary platforms:
    The first platform, ONCOS, uses oncolytic viruses as potential multi-target, neo-antigen therapeutic cancer vaccines.
  • ONCOS uses an adenovirus that has been engineered to be an immune activator that selectively targets cancer cells.
  • Additionally, Targovax has other products in early stages of development.

Targovax to Present at Jefferies 2018 Global Healthcare Conference

Retrieved on: 
Monday, June 4, 2018
Vaccination, Medicine, Experimental cancer treatments, Clinical medicine, Oncolytic virus, Cancer vaccine, Health, Cancer immunotherapy, Vaccine, Adenoviridae, Virotherapy, Virus

Targovax (OSE:TRVX) is a clinical stage company focused on developing and commercializing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors.

Key Points: 
  • Targovax (OSE:TRVX) is a clinical stage company focused on developing and commercializing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors.
  • The Company's development pipeline is based on two novel proprietary platforms:
    The first platform, ONCOS, uses oncolytic viruses as potential multi-target, neo-antigen therapeutic cancer vaccines.
  • ONCOS uses an adenovirus that has been engineered to be an immune activator that selectively targets cancer cells.
  • Additionally, Targovax has other products in early stages of development.

Elios Therapeutics Announces Interim Phase IIb Results of TLPLDC, a Personalized Therapeutic Cancer Vaccine for the Treatment of Melanoma, at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Friday, June 1, 2018
Biotechnology, Biology, Health, Biopharmaceutical, Pharmaceutical industry, Pharmacy, Cancer vaccine

The planned interim analysis was conducted after the first 120 patients enrolled in the trial had been randomized and treated for at least6 months.

Key Points: 
  • The planned interim analysis was conducted after the first 120 patients enrolled in the trial had been randomized and treated for at least6 months.
  • There was no difference in recurrence in the intent-to-treat population (TLPLDC 56.6 percent, placebo 54.1 percent, p=0.65) with 11.9 months median follow-up.
  • Elios Therapeutics, LLC, is a biopharmaceutical company developing a portfolio of innovative therapeutic cancer vaccines targeting unmet medical needs across a broad range of tumor types.
  • Given these risks and uncertainties, investors should not place undue reliance on forwardlooking statements as a prediction of actual results.

Nouscom Appoints Adrian Woolfson, M.D., Ph.D as Chief Medical Officer

Retrieved on: 
Tuesday, May 29, 2018
Vaccination, Health, Government, Vaccine, Virology, Medicine, Cancer vaccine, Chief Medical Officer, Oncology

Nouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines based on its clinically validated Exovax platform, announced today the appointment of Adrian Woolfson M.D., Ph.D. as Chief Medical Officer (CMO).

Key Points: 
  • Nouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines based on its clinically validated Exovax platform, announced today the appointment of Adrian Woolfson M.D., Ph.D. as Chief Medical Officer (CMO).
  • "We are pleased to welcome Adrian, a seasoned pharmaceutical industry executive with highly relevant immunotherapy experience, to Nouscom's management team," said Alfredo Nicosia, Chief Executive Officer of Nouscom.
  • "Nouscom is positioned to be a leading player in the neoantigen vaccine space.
  • Dr. Woolfson's clinical and post-graduate medical training was at Balliol College, Oxford, UK and Addenbrooke's Hospital Cambridge, UK.

Nouscom Appoints Adrian Woolfson, M.D., Ph.D as Chief Medical Officer

Retrieved on: 
Tuesday, May 29, 2018
Vaccination, Health, Government, Vaccine, Virology, Medicine, Cancer vaccine, Chief Medical Officer, Oncology

Nouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines based on its clinically validated Exovax platform, announced today the appointment of Adrian Woolfson M.D., Ph.D. as Chief Medical Officer (CMO).

Key Points: 
  • Nouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines based on its clinically validated Exovax platform, announced today the appointment of Adrian Woolfson M.D., Ph.D. as Chief Medical Officer (CMO).
  • "We are pleased to welcome Adrian, a seasoned pharmaceutical industry executive with highly relevant immunotherapy experience, to Nouscom's management team," said Alfredo Nicosia, Chief Executive Officer of Nouscom.
  • "Nouscom is positioned to be a leading player in the neoantigen vaccine space.
  • Dr. Woolfson's clinical and post-graduate medical training was at Balliol College, Oxford, UK and Addenbrooke's Hospital Cambridge, UK.

Personalized Cancer Vaccine Market, 2024

Retrieved on: 
Thursday, May 10, 2018
RTT, Cancer, Infectious causes of cancer, Vaccination, Medicine, Gynaecological cancer, Cancer vaccine, Vaccine, Prostate cancer, Cervical cancer, Breast cancer, Tumor antigen vaccine

Overall, the report concludes with future projections regarding the personalized cancer vaccine segment which shows an exponential growth by 2024.

Key Points: 
  • Overall, the report concludes with future projections regarding the personalized cancer vaccine segment which shows an exponential growth by 2024.
  • Global Personalized Cancer Vaccine Market Opportunity & Clinical Innovation Trend Outlook 2024 Report Highlights:
    Vaccines are therapeutics that helps protect body from disease.
  • Unlike cancer therapeutic vaccine, a preventive cancer vaccine is given to provide immunity against viruses that might cause cancer.
  • Most of the cancer vaccines under development are focused on the treatment of deadly and highly prevalent cancers such as Melanoma, breast cancer, lung cancer, prostate cancer and Cervical Cancer.